All In Biotech

Drug Trial Radar · NCT04343651

Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19

A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate Coronavirus Disease 2019 (COVID-19)

Last checked: Nov 19, 2026Latest source record: Jan 4, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

86

Actual

Start

Apr 1, 2020

Primary completion

Jul 21, 2020

Study completion Sep 20, 2021

Sponsor

Lead sponsor
CytoDyn, Inc.Industry
Sponsor type
Industry
First posted
Apr 13, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, two-arm, randomized, double blind, placebo controlled multicenter study to evaluate the safety and efficacy of leronlimab (PRO 140) in patients with mild-to-moderate symptoms of respiratory illness caused by coronavirus 2019 infection.

Conditions

  • Coronavirus Disease 2019

Interventions

  • PlaceboDrug

    Placebo

  • Leronlimab (700mg)Drug

    Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline in Total Symptom ScoreTime frame: Clinical Improvement will be assessed at baseline and at EOT (day 14).

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, Los Angeles

    Los Angeles, California

  • Palmtree Clinical Research, Inc.

    Palm Springs, California

  • Eisenhower Health

    Rancho Mirage, California

  • Yale

    New Haven, Connecticut

  • Center for Advanced Research & Education (CARE)

    Gainesville, Georgia

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Atlantic Health System Hospital

    Morristown, New Jersey

  • Montefiore Medical Center

    The Bronx, New York

  • White Plains Hospital

    White Plains, New York

  • Novant Health

    Charlotte, North Carolina

  • Ohio Health

    Columbus, Ohio

  • Oregon Health and Science University

    Portland, Oregon

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.